Free Trial

Molina Healthcare (MOH) Stock Forecast & Price Target

Molina Healthcare logo
$327.42 +7.60 (+2.38%)
As of 03:59 PM Eastern

Molina Healthcare - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
9
Buy
6

Based on 15 Wall Street analysts who have issued ratings for Molina Healthcare in the last 12 months, the stock has a consensus rating of "Hold." Out of the 15 analysts, 9 have given a hold rating, and 6 have given a buy rating for MOH.

Consensus Price Target

$365.38
11.60% Upside
According to the 15 analysts' twelve-month price targets for Molina Healthcare, the average price target is $365.38. The highest price target for MOH is $414.00, while the lowest price target for MOH is $297.00. The average price target represents a forecasted upside of 11.60% from the current price of $327.42.
Get the Latest News and Ratings for MOH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Molina Healthcare and its competitors.

Sign Up

MOH Analyst Ratings Over Time

TypeCurrent Forecast
4/30/24 to 4/30/25
1 Month Ago
3/31/24 to 3/31/25
3 Months Ago
1/31/24 to 1/30/25
1 Year Ago
5/1/23 to 4/30/24
Strong Buy
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
Hold
9 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$365.38$348.75$359.18$398.55
Forecasted Upside11.60% Upside5.86% Upside14.66% Upside16.50% Upside
Consensus Rating
Hold
Moderate Buy
Hold
Hold

MOH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MOH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Molina Healthcare Stock vs. The Competition

TypeMolina HealthcareMedical CompaniesS&P 500
Consensus Rating Score
2.40
2.82
2.54
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside11.60% Upside3,330.28% Upside20.72% Upside
News Sentiment Rating
Positive News

See Recent MOH News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/25/2025Barclays
3 of 5 stars
Andrew Mok
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$339.00 ➝ $362.00+15.15%
4/22/2025Sanford C. Bernstein
3 of 5 stars
Lance Wilkes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$414.00+37.24%
4/15/2025Baird R W
0 of 5 stars
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/15/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Neutral$331.00 ➝ $375.00+7.47%
4/11/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Macdonald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$340.00 ➝ $400.00+16.57%
4/9/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jason Cassorla
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
4/9/2025Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ann Hynes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$376.00 ➝ $400.00+21.19%
3/5/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Stephen Baxter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$295.00 ➝ $372.00+21.56%
2/7/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kevin Caliendo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$374.00 ➝ $325.00+13.15%
2/6/2025Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Raj Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$345.00 ➝ $345.00+19.20%
12/17/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Neutral$378.00 ➝ $350.00+18.42%
10/24/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$406.00 ➝ $406.00+22.41%
7/29/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$354.00 ➝ $353.00+6.02%
7/24/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$354.00 ➝ $297.00+2.86%
7/24/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$412.00 ➝ $351.00+21.57%
3/28/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$439.00+4.90%
7/14/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$365.00+21.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 05:57 PM ET.


Should I Buy Molina Healthcare Stock? MOH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 22, 2025. Please send any questions or comments about these Molina Healthcare pros and cons to contact@marketbeat.com.

Molina Healthcare
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Molina Healthcare, Inc.:

  • The current stock price is around $321, reflecting a strong performance in the market.
  • Molina Healthcare, Inc. has a solid return on equity of over 28%, indicating effective management and profitability.
  • The company has a low debt-to-equity ratio of 0.69, suggesting a manageable level of debt compared to its equity, which can be attractive to investors looking for stability.
  • Analysts expect Molina Healthcare, Inc. to post earnings per share of 24.4 for the current year, indicating potential for growth and profitability.
  • Recent upgrades from analysts, including a shift from "hold" to "buy" ratings, suggest positive sentiment and confidence in the company's future performance.

Molina Healthcare
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Molina Healthcare, Inc. for these reasons:

  • The company reported earnings per share of $5.05, which missed analysts' expectations, indicating potential challenges in meeting growth targets.
  • Molina Healthcare, Inc. has a net margin of only 2.90%, which may raise concerns about its profitability compared to competitors.
  • Insider ownership is relatively low at 1.10%, which could suggest a lack of confidence from those closest to the company.
  • The stock has experienced fluctuations, with a 52-week high of $370.99 and a low of $262.32, indicating volatility that may deter risk-averse investors.
  • Despite recent positive analyst ratings, the overall average rating remains a "Hold," suggesting that some analysts are cautious about the stock's future performance.

MOH Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Molina Healthcare is $365.38, with a high forecast of $414.00 and a low forecast of $297.00.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molina Healthcare in the last year. There are currently 9 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MOH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOH, but not buy additional shares or sell existing shares.

According to analysts, Molina Healthcare's stock has a predicted upside of 11.60% based on their 12-month stock forecasts.

Over the previous 90 days, Molina Healthcare's stock had 1 upgrade and 1 downgrade by analysts.

Molina Healthcare has been rated by research analysts at Baird R W, Barclays, Guggenheim, Mizuho, Robert W. Baird, Sanford C. Bernstein, Stephens, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.

Analysts like Molina Healthcare less than other "medical" companies. The consensus rating for Molina Healthcare is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MOH compares to other companies.


This page (NYSE:MOH) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners